Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | RECQL | P46063 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | CDC25A | P30304 | 1/20 | 0.40 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2912362 | 0.86 | RAB9A (0.47) | NPC1RAB9ARECQLALDH1A1TDP1 | |
| Phosphoric Acid SCHEMBL5395707 | 0.82 | NPC1 (0.64) | NPC1RAB9ARECQLALDH1A1TDP1 | |
| SCHEMBL8641241 | 0.81 | LMNA (0.44) | ALDH1A1TDP1KMT2ASMN1; SMN2MEN1 | |
| Phosphoric Acid SCHEMBL5395714 | 0.80 | RAB9A (0.60) | NPC1RAB9ARECQLALDH1A1TDP1 | |
| SCHEMBL14691027 | 0.80 | LMNA (0.43) | RECQLALDH1A1TDP1KMT2ASMN1; SMN2 | |
| SCHEMBL1263901 | 0.80 | LMNA (0.43) | ALDH1A1KMT2ASMN1; SMN2MEN1MAPK1 | |
| SCHEMBL8154893 | 0.79 | LMNA (0.47) | TDP1SMN1; SMN2LMNAL3MBTL1ESR1 | |
| SCHEMBL549432 | 0.78 | CA1 (0.54) | ALDH1A1SMN1; SMN2MAPTMAPK1LMNA | |
| SCHEMBL1085919 | 0.77 | HTT (0.44) | ALDH1A1TDP1KMT2ASMN1; SMN2HTT | |
| Choline SCHEMBL28307532 | 0.76 | ALDH1A1 (0.45) | NPC1RAB9ARECQLALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388630-A1 | FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR USING RECOMBINANT BACTERIA | SPOGEN BIOTECH INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12391729-B2 | Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria | SPOGEN BIOTECH INC. (US) | 2025-08-19 | — | — | US | disclosed |
| CN-119997981-A | Particulate compositions comprising peptides and uses thereof | 塔西亚制药公司 | 2025-05-13 | — | — | CN | disclosed |
| US-20240425840-A1 | FUSION PROTEINS, RECOMBINANT BACTERIA, AND EXOSPORIUM FRAGMENTS FOR PLANT HEALTH | SPOGEN BIOTECH INC (US) | 2024-12-26 | — | — | US | disclosed |
| EP-3790946-B1 | PROCESS FOR ENZYMATIC OIL DEGUMMING | DSM IP ASSETS BV (NL) | 2024-10-09 | — | — | EP | disclosed |
| US-12031164-B2 | Fusion proteins, recombinant bacteria, and exosporium fragments for plant health | SPOGEN BIOTECH INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240199709-A1 | FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR USING RECOMBINANT BACTERIA | SPOGEN BIOTECH INC (US) | 2024-06-20 | — | — | US | disclosed |
| US-11999923-B2 | Process for enzymatic oil degumming | DSM IP ASSETS B.V. (NL) | 2024-06-04 | — | — | US | disclosed |
| US-11905315-B2 | Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria | SPOGEN BIOTECH INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-20210179672-A1 | FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR USING RECOMBINANT BACTERIA | GENISYS CREDIT UNION | 2021-06-17 | — | — | US | disclosed |
| US-20170347664-A1 | FUSION PROTEINS, RECOMBINANT BACTERIA, AND EXOSPORIUM FRAGMENTS FOR ANIMAL HEALTH AND AQUACULTURE | GENISYS CREDIT UNION | 2017-12-07 | — | — | US | disclosed |
| WO-2017186890-A1 | COMPOSITIONS FOR BAKED PRODUCTS CONTAINING LIPOLYTIC ENZYMES AND USES THEREOF | PURATOS NV (BE) | 2017-11-02 | — | — | WO | disclosed |
| WO-2017186891-A1 | IMPROVED BAKERY PRODUCTS | PURATOS NV (BE) | 2017-11-02 | — | — | WO | disclosed |
| WO-2016162456-A1 | PHOSPHOLIPASE C | DSM IP ASSETS B.V. (NL) | 2016-10-13 | — | — | WO | disclosed |
| US-20160108096-A1 | FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR USING RECOMBINANT BACTERIA | GENISYS CREDIT UNION | 2016-04-21 | — | — | US | disclosed |
| EP-1418429-B1 | METHOD OF QUANTIFYING DENATURED LIPOPROTEIN | KYOWA MEDEX CO LTD (JP) | 2010-08-25 | — | — | EP | disclosed |
| US-20040241744-A1 | Method of quantifying denatured lipoprotein, reagents for quantifying denatured lipoprotein, method of detecting circulatory disease and reagents for detecting circulatory disease | KYOWA MEDEX CO. LTD. (JP) | 2004-12-02 | — | — | US | disclosed |
| EP-1418429-A1 | METHOD OF QUANTIFYING DENATURED LIPOPROTEIN, REAGENTS FOR QUANTIFYING DENATURED LIPOPROTEIN, METHOD OF DETECTING CIRCULATORY DISEASE AND REAGENTS FOR DETECTING CIRCULATORY DISEASE | KYOWA MEDEX CO., LTD. (JP) | 2004-05-12 | — | — | EP | disclosed |
| US-5910573-A | NONCOVALENT DIMER OF TWO FUSION PROTEINS EACH HAVING SINGLE CHAIN VARIABILITY FRAGMENTS OF ANTIBODY, LINEAR PEPTIDE, AND AMPHIPHATIC HELICAL PEPTIDE FOR INTERACTION | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1999-06-08 | — | — | US | disclosed |
| EP-0654085-B1 | MONOMERIC AND DIMERIC ANTIBODY-FRAGMENT FUSION PROTEINS | MERCK PATENT GMBH (DE) | 1997-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388630-A1 | FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR USING RECOMBINANT BACTERIA | MAX, SEC62, GHITM | NPC1 4362/4885RAB9A 968/4885RECQL 3103/4885 |
| US-12031164-B2 | Fusion proteins, recombinant bacteria, and exosporium fragments for plant health | ENGASE, LCT, CPB1 | NPC1 4261/4885RAB9A 2525/4885RECQL 1550/4885 |
| US-20240425840-A1 | FUSION PROTEINS, RECOMBINANT BACTERIA, AND EXOSPORIUM FRAGMENTS FOR PLANT HEALTH | ENGASE, LCT, CPB1 | NPC1 4261/4885RAB9A 2525/4885RECQL 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.